Brenipatide vs Placebo for Uncontrolled Severe Asthma
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
- Age
- 18 – 75
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 531 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
This trial is looking for adults with moderate to severe asthma who have trouble controlling their symptoms. Participants will receive either the study drug, brenipatide, or a placebo over about 65 weeks.
You may be able to join if
- I have been diagnosed with asthma.
- I have used asthma controller medication for at least 12 months.
- I have an asthma control questionnaire score of 1.5 or higher on 2 out of 3 visits.
- I had one severe asthma attack treated with glucocorticoids in the last year.
You may not be able to join if
- I have a diagnosis of occupational asthma.
- I have a serious lung condition other than asthma.
- I have a current or recent active infection.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your EligibilityThe purpose of this study is to assess the safety and efficacy of brenipatide at different dose levels compared with placebo in participants with moderate-to-severe asthma. Study participation will last approximately 65 weeks, including screening, treatment, and follow-up periods.
Loading trial locations…
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
317-615-4559
CONTACT
Physicians interested in becoming principal investigators please contact
clinical_inquiry_hub@lilly.com
CONTACT